BGM0504 is being developed in both oral and subcutaneous formulations as part of the Company's broader strategy in obesity ...

Scientists at City of Hope and TGen (part of City of Hope) are the first to explain a major mechanism for why gaining excess ...

A new study ranks Memphis as the third most obese city in the US, highlighting its high rates of diabetes and high blood ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the ...

America has an unfortunate weight problem. Not just stereotypically, but statistically, 42% of adults in the United States ...

Eli Lilly has won FDA approval for its oral obesity drug Foundayo™ (orforglipron), but the stock bounce was short lived as ...

Conclusions: Prevalence of obesity is increasing, and use of GLP-1 RAs as the preferred antiobesity medication has increased ...

The daily pill called Foundayo got a fast track through the Food and Drug Administration. It will compete with the pill form ...

Currax Pharmaceuticals LLC ("Currax") today recognizes the publication of the Joint Expert Guidance Statement on the ...

FDA clears 7.2 mg version of blockbuster obesity drug as demand for weight-loss treatments continues to surge globally ...

Compounded GLP-1 medications help fill a necessary gap, but can have significant safety issues. Compounded GLP-1 medications are largely unregulated and may contain contaminated ingredients. Stronger ...

The Food and Drug Administration's decision Wednesday means patients in the United States will soon have access to a second ...